

2011 OPA Midyear Meeting Program Learning Objectives

ACPE #0129-0000-11-056-L04-P

Medical Homes, Accountable Care Organizations, and Pharmacists

Theodore E. Wymyslo, M.D., Director, Ohio Department of Health; and Bella Mehta, R.Ph., PharmD, Associate Professor of Clinical Pharmacy, The Ohio State University College of Pharmacy

At the completion of this activity, the participant will be able to:

- 1) Differentiate patient-centered medical home and accountable care organizations;
- 2) Describe opportunities for pharmacists within the patient-centered medical home;
- 3) Explain a model of how pharmacists, in conjunction with interdisciplinary health care teams, promote wellness and optimize medication use of patients with chronic conditions in a medical home; and
- 4) Describe strategies used to obtain payment for services provided by pharmacists within a medical home.

ACPE #0129-0000-11-057-L01-P

Celiac Disease and the Gluten-Free Diet

Mary K. Sharrett, MS, RD, LD, CNSD

Nutrition Support Dietitian, Nationwide Children's Hospital, Columbus

At the completion of this activity, the participant will be able to:

- 1) Identify the incidence/prevalence of celiac disease in the United States;
- 2) Identify the symptoms of undiagnosed or untreated celiac disease;
- 3) Recognize ingredients that need to be eliminated on the gluten-free diet;
- 4) Identify resources available for clients following the gluten-free diet;
- 5) Discuss the evidence for using the gluten-free diet in conditions other than celiac disease; and
- 6) Identify nutrients that may be deficient in the gluten-free diet.

ACPE #0129-0000-11-058-L04-P

Personalized Medicine

David Kisor, R.Ph, PharmD, Chair and Professor of Pharmacokinetics

Raabe College of Pharmacy, Ohio Northern University

At the completion of this activity, the participant will be able to:

- 1) Define “personalized medicine (pharmacogenomics)” and distinguish pharmacogenomics from pharmacogenetics;
- 2) Identify the genetic basis for pharmacokinetic differences in how a drug is “handled” by a given patient;
- 3) Recognize the genetic basis of therapy with clopidogrel, warfarin, and other drugs; and
- 4) Describe the current state of “personalized medicine” relative to medical/pharmacy education; healthcare information technology; regulations; technology and tools; insurance coverage and reimbursement; and genetic privacy and legal protections.

ACPE #0129-0000-11-059-L01-P

Case Studies in the Metabolic Syndrome

David R. Bright, PharmD, Assistant Professor of Pharmacy Practice

Raabe College of Pharmacy, Ohio Northern University

At the completion of this activity, the participant will be able to:

- 1) Define the metabolic syndrome and its characteristics;

- 2) Describe the metabolic syndrome and its impact to patients and health care professionals;
- 3) Properly assess patients for the metabolic syndrome based on the most recent clinical definitions; and
- 4) Create appropriate care plans for patients with the metabolic syndrome.

ACPE #0129-0000-11-060-L04-P

Community and Hospital Pharmacists Collaborating to Decrease Hospital Readmissions

Tim Colburn, MBA, FACHE, President & CEO, Berger Health System, Circleville, Ohio and Joseph Dula, PharmD, Regional Director of Clinical Services, Pharmacy Systems, Inc.

At the completion of this activity, the participant will be able to:

- 1) Describe the value and impact of pharmacist involvement on cost of treatment and patient safety to hospital administration, physicians, and nurses;
- 2) Explain the role of the pharmacist in improving reimbursement related to Value Based Purchasing;
- 3) Recognize the severity of hospital readmissions and the need to find creative ways to positively impact the current trend; and
- 4) Identify ways to partner with community (retail/outpatient) pharmacies to foster continuity of care and facilitate consistent application of medication therapy management activities.

ACPE #0129-0000-11-061-L01-P

Current Concepts in Prostate Cancer Treatment

Curtis D. Black, R.Ph., PhD, Distinguished University Professor Emeritus College of Pharmacy & Pharmaceutical Sciences, The University of Toledo

At the completion of this activity, the participant will be able to:

- 1) Discuss the key issues surrounding differing opinions on the value of current methods for prostate cancer screening;
- 2) Highlight comparative outcomes and unintended effects of current treatment approaches for localized prostate cancer;
- 3) Cite the goals of treatment for metastatic prostate cancer; and
- 4) Explain the concept of, and current place in therapy for, tumor vaccines in the treatment of prostate cancer.

ACPE #0129-0000-11-062-L03-P

Ohio Pharmacy Law Update: Fall 2011

William Winsley, R.Ph., Executive Director, Ohio State Board of Pharmacy

At the completion of this activity, the participant will be able to:

- 1) Identify recent and proposed changes in state laws and regulations which impact the practice of pharmacy;
- 2) Discuss the importance of accuracy in prescription data submitted to the Ohio Automated Rx Reporting System (OARRS) and how the data can be used to identify potential prescription drug abuse;
- 3) Describe key elements of HB 93 (pain management clinic legislation) and their impact on medical and pharmacy practice;
- 4) Explain the status of proposed rules of the Drug Enforcement Administration for drug destruction and collection; and
- 5) Apply the board of pharmacy rules to the practice of pharmacy.

ACPE #0129-0000-11-063-L04-P

OSHA Compliance: Required Training for Needlestick Safety

Donald Bennett, R.Ph., MBA, Director of Professional Experiential Programs

The Ohio State University College of Pharmacy

At the completion of this activity, the participant will be able to:

- 1) Describe three ways needle stick injuries occur;
- 2) Describe safer practices designed to reduce/avoid needle stick and other sharps injuries; and
- 3) List the key components of a policy and procedure that meets OSHA's requirements for safe needle/sharps practices.